AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30897289 — intervention group
Group type: EXPERIMENTAL
Intervention: haplotype T-A-C (rs1998374-rs2255326-rs911887)
Number of subjects: 396
Study 28480799 — intervention group
Group type: EXPERIMENTAL
Intervention: Employed at 7 months postpartum
Number of subjects: 124
Study 28480799 — intervention group
Group type: COMPARATOR
Intervention: Not employed at 7 months postpartum
Number of subjects: 124
Study 28480799 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-time employment
Number of subjects: 124
Study 28480799 — intervention group
Group type: EXPERIMENTAL
Intervention: Part-time employment
Number of subjects: 124
Study 25559877 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive executive function training
Number of subjects: 25
Study 25559877 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 25
Study 22703532 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone 50 μg orally
Number of subjects: 12
Study 22703532 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 50 mg intravenously
Number of subjects: 12
Study 22703532 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone and Hydrocortisone (combined)
Number of subjects: 12
Study 22703532 — intervention group
Group type: COMPARATOR
Intervention: Placebo for Fludrocortisone
Number of subjects: 12
Study 22703532 — intervention group
Group type: COMPARATOR
Intervention: Placebo for Hydrocortisone
Number of subjects: 12
Study 21656143 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary pulmonary rehabilitation program for 3 months
Number of subjects: 34
Study 21656143 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 34
Study 18094720 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole
Number of subjects: 143
Study 18094720 — intervention group
Group type: COMPARATOR
Intervention: High-dose lipid formulation of amphotericin B (HD‐LPD/AMB)
Number of subjects: 143
Study 18094720 — intervention group
Group type: COMPARATOR
Intervention: Caspofungin plus HD‐LPD/AMB
Number of subjects: 143
Study 16137898 — intervention group
Group type: EXPERIMENTAL
Intervention: VNUS
Number of subjects: 16
Study 16137898 — intervention group
Group type: COMPARATOR
Intervention: RGS
Number of subjects: 16
Study 12968233 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional ischemic preconditioning (IP)
Number of subjects: 32
Study 12968233 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study 11027806 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hepatitis A and B vaccine (HAB)
Number of subjects: 80
Study 11027806 — intervention group
Group type: COMPARATOR
Intervention: Concomitant hepatitis A and B vaccines (HAV + HBV)
Number of subjects: 80
Study 8622062 — intervention group
Group type: EXPERIMENTAL
Intervention: BU/CY
Number of subjects: 14
Study 8622062 — intervention group
Group type: COMPARATOR
Intervention: CY/TBI
Number of subjects: 14
Study 1610421 — intervention group
Group type: EXPERIMENTAL
Intervention: Domiodol 60 mg t.i.d.
Number of subjects: 20
Study 1610421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6369431 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg morphine intrathecally (spinal group)
Number of subjects: 29
Study 6369431 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg body weight of morphine i.v. (i.V. group)
Number of subjects: 29
Study 6369431 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg body weight epidurally (PDA group)
Number of subjects: 29
Study 6369431 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal and epidural opiates
Number of subjects: 29
Study 6369431 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF morphine concentration 24 hrs after injection
Number of subjects: 29
Study 30995657 — intervention group
Group type: EXPERIMENTAL
Intervention: F + V (fruits and vegetables)
Number of subjects: 108
Study 30995657 — intervention group
Group type: EXPERIMENTAL
Intervention: HCO3 (oral sodium bicarbonate)
Number of subjects: 108
Study 30995657 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 108
Study 30291483 — intervention group
Group type: EXPERIMENTAL
Intervention: 400-μg misoprostol rectally with 5-IU oxytocin IV
Number of subjects: 636
Study 30291483 — intervention group
Group type: EXPERIMENTAL
Intervention: 400-μg misoprostol sublingually with 5-IU oxytocin IV
Number of subjects: 636
Study 30291483 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 5-IU oxytocin IV
Number of subjects: 636
Study 30291483 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between sublingual and rectal misoprostol
Number of subjects: 636
Study 25800768 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care (PC) consultation, structured PC telehealth nurse coaching sessions (once per week for six sessions), and monthly follow-up
Number of subjects: 207
Study 25800768 — intervention group
Group type: COMPARATOR
Intervention: Delayed palliative care (PC) consultation, structured PC telehealth nurse coaching sessions (once per week for six sessions), and monthly follow-up
Number of subjects: 207
Study 25800768 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care (PC)
Number of subjects: 207
Study 25800768 — intervention group
Group type: COMPARATOR
Intervention: Delayed palliative care (PC)
Number of subjects: 207
Study 23684814 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-barrel approach (DBA)
Number of subjects: 0
Study 23684814 — intervention group
Group type: COMPARATOR
Intervention: Classic canine fossa puncture (CFP)
Number of subjects: 0
Study 23684814 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DBA and CFP
Number of subjects: 0
Study 21412231 — intervention group
Group type: COMPARATOR
Intervention: Lorcaserin (20 mg)
Number of subjects: 35
Study 21412231 — intervention group
Group type: COMPARATOR
Intervention: Lorcaserin (supratherapeutic doses)
Number of subjects: 35
Study 21412231 — intervention group
Group type: COMPARATOR
Intervention: Lorcaserin (all doses)
Number of subjects: 35
Study 21412231 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem (15 and 30 mg)
Number of subjects: 35
Study 21412231 — intervention group
Group type: COMPARATOR
Intervention: Ketamine (100 mg)
Number of subjects: 35
Study 21412231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 19536092 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin and capecitabine treatment
Number of subjects: 91
Study 17825709 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic hemodialysis
Number of subjects: 82
Study 14996351 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alpha 2a (pegIFNalpha 2a)
Number of subjects: 412
Study 14996351 — intervention group
Group type: COMPARATOR
Intervention: IFNalpha 2b/RBV
Number of subjects: 412
Study 11398690 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction system (CS)
Number of subjects: 10
Study 11398690 — intervention group
Group type: COMPARATOR
Intervention: Open suction system (OS)
Number of subjects: 10
Study 9580448 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamizol 2 g
Number of subjects: 253
Study 9580448 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamizol 1 g
Number of subjects: 253
Study 9580448 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 600 mg
Number of subjects: 253
Study 9580448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study 10179576 — intervention group
Group type: EXPERIMENTAL
Intervention: Back-propagation neural network
Number of subjects: 0
Study 10179576 — intervention group
Group type: EXPERIMENTAL
Intervention: Discriminant analysis
Number of subjects: 0
Study 10179576 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 0
Study 10179576 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster analysis
Number of subjects: 0
Study 1778353 — intervention group
Group type: EXPERIMENTAL
Intervention: Active policy with either insulin or sulphonylurea aiming to reduce fasting plasma glucose to under 6 mmol/l
Number of subjects: 5100
Study 1778353 — intervention group
Group type: COMPARATOR
Intervention: Diet policy
Number of subjects: 5100
Study 1778353 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight control aiming for less than 150/85 mm Hg with either an angiotensin‐converting enzyme inhibitor or a Beta‐blocker
Number of subjects: 5100
Study 1778353 — intervention group
Group type: COMPARATOR
Intervention: Less tight control aiming for less than 200/105 mm Hg
Number of subjects: 5100
Study 1778353 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogate endpoints
Number of subjects: 5100
Study 6756327 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP (10 cm H2O)
Number of subjects: 83
Study 6756327 — intervention group
Group type: COMPARATOR
Intervention: No PEEP (zero end-expiratory pressure)
Number of subjects: 83
Study 31927343 — intervention group
Group type: EXPERIMENTAL
Intervention: CVT‐301 84 mg
Number of subjects: 408
Study 31927343 — intervention group
Group type: COMPARATOR
Intervention: Observational cohort (OC) receiving oral standard of care
Number of subjects: 408
Study 31105006 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based training
Number of subjects: 47
Study 29228795 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A eye ointment (VAEO) administered every 6 hr for 5 days
Number of subjects: 38
Study 29228795 — intervention group
Group type: COMPARATOR
Intervention: Moist chamber (MC) with polyethylene cover replaced every 12 hr
Number of subjects: 38
Study 26404953 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 0.5 μg calcitriol, 75 mg acetylsalicylic acid, and 1250 mg calcium carbonate (n = 209)
Number of subjects: 1107
Study 26404953 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 218)
Number of subjects: 1107
Study 26404953 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis for nonsmokers
Number of subjects: 1107
Study 26404953 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis for current smokers
Number of subjects: 1107
Study 24121464 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led delirium rounds with unit champions, average duration 25.54 min (SD = 13.18)
Number of subjects: 192
Study 24121464 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple strategies and local opinion leader/unit champion
Number of subjects: 192
Study 22537957 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin treatment (1.0×10(4) U/kg)
Number of subjects: 50
Study 22537957 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 19995589 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% ethanol for 30s, 70% ethanol for 30s, 80% ethanol for 30s, 95% ethanol for 30s, 100% ethanol for 30s (Group 1)
Number of subjects: 30
Study 19995589 — intervention group
Group type: COMPARATOR
Intervention: Adper Scotchbond Multi‐Purpose (Control Group)
Number of subjects: 30
Study 19995589 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol dehydration with 15s for each solution (Group 2)
Number of subjects: 30
Study 19995589 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% ethanol applied in seven 30s steps (Group 3)
Number of subjects: 30
Study 19995589 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% ethanol applied in three 30s steps (Group 4)
Number of subjects: 30
Study 19995589 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% ethanol applied in one 30s step (Group 5)
Number of subjects: 30
Study 18585508 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab bolus-only (0.25 mg/kg)
Number of subjects: 1005
Study 18585508 — intervention group
Group type: COMPARATOR
Intervention: Abciximab bolus + infusion (0.125 microg/[kg min] for 12 hours)
Number of subjects: 1005
Study 16188769 — intervention group
Group type: EXPERIMENTAL
Intervention: Paediatric care
Number of subjects: 320
Study 16188769 — intervention group
Group type: COMPARATOR
Intervention: Primary care
Number of subjects: 320
Study 16188769 — intervention group
Group type: EXPERIMENTAL
Intervention: Both settings
Number of subjects: 320
Study 12121427 — intervention group
Group type: EXPERIMENTAL
Intervention: One daily bout of walking (Group S1)
Number of subjects: 134
Study 12121427 — intervention group
Group type: EXPERIMENTAL
Intervention: Two daily bouts of walking (Group S2)
Number of subjects: 134
Study 10080677 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN) - 37 kcal/kg/day + 2.0 g proteins/kg/day for 34 days
Number of subjects: 50
Study 10080677 — intervention group
Group type: COMPARATOR
Intervention: Standard Oral Diet (SD)
Number of subjects: 50
Study 7942245 — intervention group
Group type: EXPERIMENTAL
Intervention: Social influences smoking prevention program
Number of subjects: 100
Study 7942245 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 100
Study 2833577 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, doxorubicin, and cisplatin (CAP)
Number of subjects: 233
Study 2833577 — intervention group
Group type: EXPERIMENTAL
Intervention: Vindesine and cisplatin (VP)
Number of subjects: 233
Study 2833577 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 233
Study 2833577 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (VP and CAP combined)
Number of subjects: 233
Study 29169967 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification program (telephonic coaching, free of charge)
Number of subjects: 451
Study 29169967 — intervention group
Group type: COMPARATOR
Intervention: Noncompliant subjects (less than 78.5% of calls or refused to participate)
Number of subjects: 451
Study 27776543 — intervention group
Group type: EXPERIMENTAL
Intervention: Local HbA1c measurements
Number of subjects: 255
Study 27776543 — intervention group
Group type: COMPARATOR
Intervention: Central HbA1c measurements
Number of subjects: 255
Study 24962635 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemigliptin 50 mg once daily for 6 days + Glimepiride 4 mg on day 7
Number of subjects: 23
Study 24962635 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride 4 mg single dose
Number of subjects: 23
Study 20524875 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutathione, 500 mg/day for 4 weeks
Number of subjects: 60
Study 20524875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 20524875 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutathione
Number of subjects: 60
Study 20512260 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy group (PG) - kinesiotherapy for upper limbs with 19 exercises, 10 rhythmic repetitions or stretching movements.
Number of subjects: 55
Study 20512260 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - no physiotherapy.
Number of subjects: 55
Study 20512260 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy group (PG) - kinesiotherapy for upper limbs.
Number of subjects: 55
Study 18942124 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients excluded from randomization after PCI
Number of subjects: 343
Study 18942124 — intervention group
Group type: COMPARATOR
Intervention: Randomized patients
Number of subjects: 343
Study 18942124 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient vessel closure post-PCI
Number of subjects: 343
Study 18942124 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual dissection >or= grade B post-PCI
Number of subjects: 343
Study 15824216 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin infusion with reduced fluence (RF) rate (300 mW/cm² for 83 seconds, light dose of 25 J/cm²)
Number of subjects: 117
Study 15824216 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin infusion with standard fluence (SF) rate (600 mW/cm² for 83 seconds, light dose of 50 J/cm²)
Number of subjects: 117
Study 15824216 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 117
Study 12913718 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary plus booster immunizations (6 vaccine doses)
Number of subjects: 54
Study 12913718 — intervention group
Group type: COMPARATOR
Intervention: Placebo only
Number of subjects: 54
Study 12913718 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary immunization (3 doses of vaccine)
Number of subjects: 54
Study 10673872 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-nitrous oxide
Number of subjects: 44
Study 10673872 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-alfentanil-nitrous oxide
Number of subjects: 44
Study 10673872 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 44
Study 8923161 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine (dF) 15 mg bd
Number of subjects: 84
Study 8923161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 1352949 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 30
Study 1352949 — intervention group
Group type: COMPARATOR
Intervention: Sodium Nitroprusside (SNP)
Number of subjects: 30
Study 6148025 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 8 micrograms/kg intravenously prior to induction with etomidate
Number of subjects: 50
Study 6148025 — intervention group
Group type: COMPARATOR
Intervention: Halothane as required to maintain adequate anaesthesia
Number of subjects: 50
Study 31378043 — intervention group
Group type: EXPERIMENTAL
Intervention: Male students
Number of subjects: 2521
Study 31378043 — intervention group
Group type: COMPARATOR
Intervention: High peer acceptance
Number of subjects: 2521
Study 31378043 — intervention group
Group type: COMPARATOR
Intervention: High family intimacy
Number of subjects: 2521
Study 31378043 — intervention group
Group type: COMPARATOR
Intervention: More physical activity
Number of subjects: 2521
Study 31378043 — intervention group
Group type: COMPARATOR
Intervention: Mother's education level (junior high school and above)
Number of subjects: 2521
Study 31378043 — intervention group
Group type: COMPARATOR
Intervention: Mother's education level (bachelor's degree or above)
Number of subjects: 2521
Study 29208347 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone-hydrogel bandage contact lens (BCL)
Number of subjects: 51
Study 29208347 — intervention group
Group type: COMPARATOR
Intervention: No bandage contact lens (Control)
Number of subjects: 51
Study 27260252 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile communications for exclusive breastfeeding counselling (text messages 2-3 times per week)
Number of subjects: 35
Study 25340832 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozenoxacin 1% cream
Number of subjects: 0
Study 25340832 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 0
Study 25340832 — intervention group
Group type: COMPARATOR
Intervention: Retapamulin 1% ointment
Number of subjects: 0
Study 22759797 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled treprostinil
Number of subjects: 178
Study 22759797 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled treprostinil (upper quartile of NT-proBNP)
Number of subjects: 178
Study 22759797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 22759797 — intervention group
Group type: COMPARATOR
Intervention: Placebo (upper quartile of NT-proBNP)
Number of subjects: 178
Study 22759797 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of least-squares mean difference in 6MWD
Number of subjects: 178
Study 20082236 — intervention group
Group type: EXPERIMENTAL
Intervention: LEF-anti-TNF-alpha combination therapy
Number of subjects: 120
Study 20082236 — intervention group
Group type: COMPARATOR
Intervention: MTX-anti-TNF-alpha combination therapy
Number of subjects: 120
Study 17587447 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (specific chemotherapy not detailed)
Number of subjects: 529
Study 16234514 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, epirubicin, and fluorouracil (CEF); n = 480
Number of subjects: 980
Study 16234514 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, and fluorouracil (CMF); n = 500
Number of subjects: 980
Study 12049444 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training (PT) program for preschool ADHD, 8-week duration
Number of subjects: 83
Study 9856931 — intervention group
Group type: EXPERIMENTAL
Intervention: Less aggressive burst stimulation
Number of subjects: 0
Study 9856931 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ventricular tachycardia cycle length
Number of subjects: 0
Study 9856931 — intervention group
Group type: EXPERIMENTAL
Intervention: 91% coupling interval
Number of subjects: 0
Study 8521431 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish
Number of subjects: 254
Study 8521431 — intervention group
Group type: COMPARATOR
Intervention: Acidulated phosphate fluoride (APF) gel
Number of subjects: 254
Study 2191587 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 53
Study 2191587 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 53
Study 2191587 — intervention group
Group type: COMPARATOR
Intervention: Altizide + Spironolactone
Number of subjects: 53
Study 365429 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 20
Study 365429 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 20
Study 31148344 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists' training on pharmacovigilance
Number of subjects: 422
Study 31148344 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists' beliefs about synthetic drugs
Number of subjects: 422
Study 31148344 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists' beliefs about natural drugs
Number of subjects: 422
Study 31148344 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists' opinions on reporting adverse reactions of natural drugs
Number of subjects: 422
Study 28706166 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional coaching program (8 sessions of 60 minutes each)
Number of subjects: 70
Study 26536871 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (PTX) alone (80 mg/m², d1; n=47)
Number of subjects: 141
Study 26536871 — intervention group
Group type: EXPERIMENTAL
Intervention: Iniparib plus weekly Paclitaxel (PWI) (11.2 mg/kg, d1; n=46)
Number of subjects: 141
Study 26536871 — intervention group
Group type: EXPERIMENTAL
Intervention: Iniparib plus twice-weekly Paclitaxel (PTI) (5.6 mg/kg, d1, 4; n=48)
Number of subjects: 141